Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04604197 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ANGiographic Evaluation of Left Main Coronary Artery INtErvention

Study acronym: ANGELINE
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Mar 1, 2026 → Mar 31, 2027
See other at-risk trials from Fundación EPIC

Record History

  1. Primary completion pushed from Mar 1, 2026 to Mar 31, 2027 Completion pushed from Apr 1, 2026 to Apr 30, 2027 · Eligibility criteria expanded, about 11 words · Secondary endpoints: details revised at 1 of 8 entries · 3 more Show 6 more changesShow less
    • Completion pushed from Apr 1, 2026 to Apr 30, 2027
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 1 of 8 entries
    • Study description revised
    • Site details revised at 1 of 30 sites
    • Publications: details revised at 6 of 6 entries
  2. Primary completion date: Dec 1, 2025 to Mar 1, 2026 Completion date: Dec 1, 2025 to Apr 1, 2026v27 Show 1 more changeShow less
    • Completion date: Dec 1, 2025 to Apr 1, 2026
  3. Trial status: Recruiting to Active, Not Recruiting Site details revised at 30 of 30 sitesv26 Show 1 more changeShow less
    • Site details revised at 30 of 30 sites
  4. Re-verified, no change to tracked fieldsv25
  5. Eligibility criteria expanded, about 38 wordsv24 See this version in full on ClinicalTrials.gov ↗
Show 22 earlier versionsHide 22 earlier versions
  1. Study sites: 29 to 30v23
  2. Study sites: 28 to 29v22
  3. Study sites: 27 to 28v21
  4. Study sites: 26 to 27v20
  5. Study sites: 25 to 26v19
  6. Study sites: 24 to 25v18
  7. Study sites: 23 to 24v17
  8. Study sites: 20 to 23v16
  9. Study sites: 18 to 20v15
  10. Study sites: 16 to 18v14
  11. Study sites: 14 to 16v13
  12. Study sites: 13 to 14v12
  13. Study sites: 12 to 13v11
  14. Study sites: 10 to 12v10
  15. Study sites: 9 to 10v9
  16. Study sites: 8 to 9v8
  17. Study sites: 7 to 8 Start date changed from estimate of Apr 20, 2021 to Apr 16, 2021v7 Show 1 more changeShow less
    • Start date changed from estimate of Apr 20, 2021 to Apr 16, 2021
  18. Study sites: 6 to 7v6
  19. Study sites: 5 to 6v5
  20. Start date: Mar 8, 2021 to Apr 20, 2021 Study sites: 2 to 5v4 Show 1 more changeShow less
    • Study sites: 2 to 5
  21. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Start date: Mar 1, 2021 to Mar 8, 2021v3 Show 2 more changesShow less
    • Study sites: 0 to 2
    • Start date: Mar 1, 2021 to Mar 8, 2021
  22. Study description expanded, about 1 wordv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To assess if an angiographic follow-up at 6 months after Percutaneous Coronary Intervention in Left Main Coronary Artery Disease decrease the composite objective of death, myocardial infarction, and stroke at 36 months.
Trial Details
NCT Number NCT04604197
Lead Sponsor Fundación EPIC
Conditions Coronary Occlusion, Left Main Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov